Comparison of Triple Antiplatelet Therapy and Dual Antiplatelet Therapy in Patients at High Risk of Restenosis After Drug-Eluting Stent Implantation (from the DECLARE-DIABETES and -LONG Trials)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Seung-Whan | - |
dc.contributor.author | Chun, Kook-Jin | - |
dc.contributor.author | Park, Seong-Wook | - |
dc.contributor.author | Kim, Hyun-Sook | - |
dc.contributor.author | Kim, Young-Hak | - |
dc.contributor.author | Yun, Sung-Cheol | - |
dc.contributor.author | Kim, Won-Jang | - |
dc.contributor.author | Lee, Jong-Young | - |
dc.contributor.author | Park, Duk-Woo | - |
dc.contributor.author | Lee, Cheol Whan | - |
dc.contributor.author | Hong, Myeong-Ki | - |
dc.contributor.author | Rhee, Kyoung-Suk | - |
dc.contributor.author | Chae, Jei Keon | - |
dc.contributor.author | Ko, Jae-Ki | - |
dc.contributor.author | Park, Jae-Hyeong | - |
dc.contributor.author | Lee, Jae-Hwan | - |
dc.contributor.author | Choi, Si Wan | - |
dc.contributor.author | Jeong, Jin-Ok | - |
dc.contributor.author | Seong, In-Whan | - |
dc.contributor.author | Jon, Suh | - |
dc.contributor.author | Cho, Yoon Haeng | - |
dc.contributor.author | Lee, Nae-Hee | - |
dc.contributor.author | Kim, June Hong | - |
dc.contributor.author | Park, Seung-Jung | - |
dc.date.accessioned | 2021-08-12T07:25:06Z | - |
dc.date.available | 2021-08-12T07:25:06Z | - |
dc.date.issued | 2010-01-15 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.issn | 1879-1913 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18065 | - |
dc.description.abstract | Although cilostazol has decreased restenosis and target lesion revascularization (TLR) after drug-eluting stent implantation, it is not known if this effect is durable at 2 years. We analyzed 2 randomized studies (Drug-Eluting stenting followed by Cilostazol treatment reduces LAte REstenosis in patients with DIABETES mellitus and Drug-Eluting Stenting Followed by Cilostazol treatment reduces LAte REstenosis in patients with LONG native coronary lesions trials) in which 900 patients were randomly assigned to triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol; triple group, n = 450) and dual antiplatelet therapy (aspirin and clopidogrel; standard group, n = 450) for 6 months in patients with diabetes or long lesions receiving drug-eluting stents. We evaluated 2-year major adverse cardiac events (MACEs) including death, myocardial infarction (MI), and TLR. Nine-month TLRs and MACEs were significantly decreased in the triple versus standard group. At 2 years, the triple group sowed significantly decreased TLRs (4.2% vs 9.1%, hazard ratio 0.45, 95% confidence interval 0.26 to 0.78, p = 0.004) and MACEs (5.6% vs 10.4%, hazard ratio 0.52, 95% confidence interval 0.32 to 0.84, p = 0.008) compared to the standard group with no differences in death and MI. In subgroup analysis, triple antiplatelet therapy decrease of 2-year TLR was favorable in all subgroups, especially in patients with paclitaxel-eluting stents, diabetes mellitus, small vessels, long lesions, and left anterior descending coronary artery lesions. In conclusion, compared to the standard group, initial benefit in decreases of 9-month TLRs and MACEs in the triple group was sustained at 2 years with no differences in death or MI. Triple antiplatelet therapy decrease of 2-year TLR was favorable in all subgroups, especially in patients with high-risk profiles. (C) 2010 Elsevier Inc. All rights reserved. (Am J Cardiol 2010;105:168-173) | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Excerpta Medica, Inc. | - |
dc.title | Comparison of Triple Antiplatelet Therapy and Dual Antiplatelet Therapy in Patients at High Risk of Restenosis After Drug-Eluting Stent Implantation (from the DECLARE-DIABETES and -LONG Trials) | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.amjcard.2009.08.667 | - |
dc.identifier.scopusid | 2-s2.0-73149120546 | - |
dc.identifier.wosid | 000278136400007 | - |
dc.identifier.bibliographicCitation | American Journal of Cardiology, v.105, no.2, pp 168 - 173 | - |
dc.citation.title | American Journal of Cardiology | - |
dc.citation.volume | 105 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 168 | - |
dc.citation.endPage | 173 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | CORONARY | - |
dc.subject.keywordPlus | PREDICTORS | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | LESIONS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.